By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DiagnoCure has received a Clinical Laboratory Permit from New York State regulators for its CLIA-approved and CAP-certified laboratory, the company announced today.

The permit from the New York State Department of Health allows DiagnoCure's lab in West Chester, Penn., to use the company's Previstage GCC Colorectal Staging Test on commercial samples originating in New York, which could crack open a significant market for the test, DiagnoCure said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.